New Ifosfamide Analogs Show Promise for Reduced Neurotoxicity and Nephrotoxicity while Maintaining Anticancer Activity

Researchers at the University of Paris have developed new ifosfamide analogs, C7, C9-dimethyl-ifosfamide, which exhibit reduced neurotoxicity and nephrotoxicity while maintaining their anticancer activity. These analogs were designed to prevent the formation of chloroacetaldehyde, a known toxic metabolite of ifosfamide. The results of in vitro biotransformation studies and cytotoxicity assays suggest that the new analogs are more effective against cancer cells and have improved pharmacokinetics.

Key Takeaways:

• The new ifosfamide analogs, C7, C9-dimethyl-ifosfamide, were designed to reduce neurotoxicity and nephrotoxicity associated with ifosfamide treatment.
• In vitro biotransformation studies showed that the analogs were metabolized through the same N-deschloroalkylation pathway as ifosfamide.
• Cytotoxicity assays on 9L rat glioblastoma cells revealed that the new analogs were 4 to 6 times more cytotoxic than ifosfamide.
• The generated dimethylated mustards from the new analogs were 28 times faster alkylating agents than ifosfamide mustards.
• The 7S,9R-enantiomer of the new analogs will be assessed for further in vivo investigations for its anticancer activity and toxicological profile.
• The aim of the research was to prevent chloroacetaldehyde formation using enantioselectively synthesized ifosfamide analogs, which could lead to reduced toxicity without compromising anticancer activity.

Statistics:

• 4 to 6 times more cytotoxic than ifosfamide on 9L cell lines
• 28 times faster alkylating agents than ifosfamide mustards
• 7S,9R-enantiomer of the new analogs will be assessed for further in vivo investigations
• In vitro biotransformation studies were performed using liquid chromatography and tandem mass spectrometry on drug-induced rat liver microsomes and human microsomes expressing the main CYP3A4 and minor CYP2B6 enzymes

Sources:

• Storme, T. et al. (2009). "New Ifosfamide Analogs Designed for Lower Associated Neurotoxicity and Nephrotoxicity with Modified Alkylating Kinetics Leading to Enhanced in Vitro Anticancer Activity." Journal of Pharmacology and Experimental Therapeutics, 328(2), 598-609.
• Cancer Weekly editors (2009). "New Ifosfamide Analogs Show Promise for Reduced Neurotoxicity and Nephrotoxicity while Maintaining Anticancer Activity." Cancer Weekly via NewsRx.com.